ReviewFrontiers in pharmacology2016
Milrinone in Enterovirus 71 Brain Stem Encephalitis.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial.Annals of medicine · 2025Trial
- Cardiac injury in children with severe hand, foot and mouth disease: risk factors and clinical outcomes.Infection · 2026Article
- Promising therapeutics of enterovirus 71 infection: sunshine behind cloud.Frontiers in pharmacology · 2025Review
- Blocking CCL3-mediated neutrophil recruitment into the brain alleviates immunopathology following severe enterovirus 71 infection.iScience · 2024Article
- Article
- Current status of hand-foot-and-mouth disease.Journal of biomedical science · 2023Review
- Drug Repositioning for Hand, Foot, and Mouth Disease.Viruses · 2022Review
- Interplays between Enterovirus A71 and the innate immune system.Journal of biomedical science · 2019Review
- A case report of a teenager with severe hand, foot, and mouth disease with brainstem encephalitis caused by enterovirus 71.BMC pediatrics · 2019Article
- A pathophysiological role of PDE3 in allergic airway inflammation.JCI insight · 2018Article
- Efficacy ofBioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus 71 (EV71) was implicated in a widespread outbreak of hand-foot-and-mouth disease (HFMD) across the Asia Pacific area since 1997 and has also been reported sporadically in patients with brain stem encephalitis. Neurogenic shock with pulmonary edema (PE) is a fatal complication of EV71 infection. Among inotropic agents, milrinone is selected as a therapeutic agent for EV71- induced PE due to its immunopathogenesis. Milrinone is a type III phosphodiesterase inhibitor that has both inotropic and vasodilator effects. Its clinical efficacy has been shown by modulating inflammation, reducing sympathetic over-activity, and improving survival in patients with EV71-associated PE. Milrinone exhibits immunoregulatory and anti-inflammatory effects in the management of systemic inflammatory responses in severe EV71 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.